Zenas Biopharma Inc
NASDAQ:ZBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zenas Biopharma Inc
NASDAQ:ZBIO
|
US |
|
Chemometec A/S
F:CHY
|
DK |
|
I
|
Insight Digital Partners II
NASDAQ:DYOR
|
US |
|
T
|
Taewoong Logistics Co Ltd
KOSDAQ:124560
|
KR |
|
Irish Residential Properties REIT PLC
F:IRES
|
IE |
|
Isramco Negev 2 LP
OTC:ISRMF
|
IL |
|
N
|
Namhwa Industrial Co Ltd
KOSDAQ:111710
|
KR |
|
Sumitomo Chemical India Ltd
NSE:SUMICHEM
|
IN |
|
D
|
Danang Housing Investment Development JSC
VN:NDN
|
VN |
|
Allot Ltd
NASDAQ:ALLT
|
IL |
|
Mastercard Inc
NYSE:MA
|
US |
|
Relief Therapeutics Holding SA
SIX:RLF
|
CH |
|
R
|
Rolls-Royce Holdings PLC
OTC:RLLCF
|
UK |
Wall Street
Price Targets
ZBIO Price Targets Summary
Zenas Biopharma Inc
According to Wall Street analysts, the average 1-year price target for ZBIO is 42.84 USD with a low forecast of 21.21 USD and a high forecast of 57.75 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ZBIO's stock price target?
Price Target
42.84
USD
According to Wall Street analysts, the average 1-year price target for ZBIO is 42.84 USD with a low forecast of 21.21 USD and a high forecast of 57.75 USD.
What is Zenas Biopharma Inc's Revenue forecast?
Projected CAGR
112%
For the last 1 year the compound annual growth rate for Zenas Biopharma Inc's revenue is -90%. The projected CAGR for the next 4 years is 112%.